Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Description

To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.

Conditions

Breast Cancer, Contrast Enhanced Ultrasound

Talk to us

Study Overview

On this page

Study Details

Study overview

To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Hershey

Penn State Health College of Medicine, Hershey, Pennsylvania, United States, 17033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Willingness and ability to sign and date the study-specific informed consent form.
  • * Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study.
  • * Age greater than 18yo.
  • * Stage I-III TNBC or stage IV TNBC with intact breast primary.
  • * Planned combined ICI therapy as per SoC by treating oncologist.
  • * Other clinical trials are not excluded but participation must be cleared with the other clinical trial PIs.
  • * Patients not suitable to undergo contrast enhanced ultrasound (i.e., pregnant women, known allergy to eggs, or a past allergic reaction to sonographic contrast or its components, such as polyethylene glycol (PEG))

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Milton S. Hershey Medical Center,

Seth Hardy, M.D., PRINCIPAL_INVESTIGATOR, Assistant Professor - Department of Radiology, Penn State Health

Study Record Dates

2031-09-01